https://www.yiliao.com/index.php?action=history&feed=atom&title=ERBB3
ERBB3 - 版本历史
2026-04-21T15:11:17Z
本wiki的该页面的版本历史
MediaWiki 1.35.1
https://www.yiliao.com/index.php?title=ERBB3&diff=311653&oldid=prev
2025年12月29日 (一) 15:59 77921020
2025-12-29T15:59:18Z
<p></p>
<table class="diff diff-contentalign-left diff-editfont-monospace" data-mw="interface">
<col class="diff-marker" />
<col class="diff-content" />
<col class="diff-marker" />
<col class="diff-content" />
<tr class="diff-title" lang="zh-Hans-CN">
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">←上一版本</td>
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">2025年12月29日 (一) 15:59的版本</td>
</tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l7" >第7行：</td>
<td colspan="2" class="diff-lineno">第7行：</td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> </div></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> </div></div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"></td></tr>
<tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div> <div class="medical-infobox mw-collapsible mw-collapsed" style="width: 100%; max-width: <del class="diffchange diffchange-inline">35</del></div></td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div> <div class="medical-infobox mw-collapsible mw-collapsed" style="width: 100%; max-width: <ins class="diffchange diffchange-inline">350px</ins>; margin: 0 auto 35px auto; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;"></div></td></tr>
<tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div><del class="diffchange diffchange-inline">0px</del>; margin: 0 auto 35px auto; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;"></div></td><td colspan="2"> </td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> </div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> </div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #e0f2fe 0%, #bae6fd 100%); text-align: center; cursor: pointer;"></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #e0f2fe 0%, #bae6fd 100%); text-align: center; cursor: pointer;"></div></td></tr>
</table>
77921020
https://www.yiliao.com/index.php?title=ERBB3&diff=311652&oldid=prev
2025年12月29日 (一) 15:58 77921020
2025-12-29T15:58:26Z
<p></p>
<table class="diff diff-contentalign-left diff-editfont-monospace" data-mw="interface">
<col class="diff-marker" />
<col class="diff-content" />
<col class="diff-marker" />
<col class="diff-content" />
<tr class="diff-title" lang="zh-Hans-CN">
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">←上一版本</td>
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">2025年12月29日 (一) 15:58的版本</td>
</tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l7" >第7行：</td>
<td colspan="2" class="diff-lineno">第7行：</td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> </div></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> </div></div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"></td></tr>
<tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div> <div class="medical-infobox mw-collapsible mw-collapsed" style="width: 100%; max-width: <del class="diffchange diffchange-inline">340px</del>; margin: 0 auto 35px auto; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;"></div></td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div> <div class="medical-infobox mw-collapsible mw-collapsed" style="width: 100%; max-width: <ins class="diffchange diffchange-inline">35</ins></div></td></tr>
<tr><td colspan="2"> </td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins class="diffchange diffchange-inline">0px</ins>; margin: 0 auto 35px auto; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;"></div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> </div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> </div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #e0f2fe 0%, #bae6fd 100%); text-align: center; cursor: pointer;"></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #e0f2fe 0%, #bae6fd 100%); text-align: center; cursor: pointer;"></div></td></tr>
</table>
77921020
https://www.yiliao.com/index.php?title=ERBB3&diff=311651&oldid=prev
77921020：建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面
2025-12-29T15:58:10Z
<p>建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面</p>
<p><b>新页面</b></p><div><div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff; max-width: 1200px; margin: auto;"><br />
<br />
<div style="margin-bottom: 30px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 25px;"><br />
<p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;"><br />
<strong>ERBB3</strong>（Erb-B2 Receptor Tyrosine Kinase 3），常被称为 <strong>HER3</strong>，编码表皮生长因子受体（EGFR/ERBB）家族的第三个成员。与家族中其他成员（EGFR, HER2, HER4）不同，ERBB3 的独特之处在于它缺乏具有催化活性的激酶结构域（Kinase-Impaired），被称为<strong>“假激酶”</strong>（Pseudokinase）。因此，它无法自我磷酸化，必须通过与 <strong>HER2</strong> 或 EGFR 形成<strong>异源二聚体</strong>来传导信号。尽管自身“武功全废”，ERBB3 却是家族中激活 <strong>PI3K/AKT</strong> 通路能力最强的成员，被认为是 HER2 驱动肿瘤（如<strong>[[乳腺癌]]</strong>）中最关键的协同伴侣，也是<strong>[[非小细胞肺癌]]</strong>对 EGFR 靶向药产生耐药的重要旁路机制。<br />
</p><br />
</div><br />
<br />
<div class="medical-infobox mw-collapsible mw-collapsed" style="width: 100%; max-width: 340px; margin: 0 auto 35px auto; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;"><br />
<br />
<div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #e0f2fe 0%, #bae6fd 100%); text-align: center; cursor: pointer;"><br />
<div style="font-size: 1.2em; font-weight: bold; letter-spacing: 1.2px;">ERBB3 (HER3) · 基因档案</div><br />
<div style="font-size: 0.7em; opacity: 0.85; margin-top: 4px; white-space: nowrap;">Gene & Protein Profile (点击展开)</div><br />
</div><br />
<br />
<div class="mw-collapsible-content"><br />
<div style="padding: 25px; text-align: center; background-color: #f8fafc;"><br />
<div style="display: inline-block; background: #ffffff; border: 1px solid #e2e8f0; border-radius: 12px; padding: 20px; box-shadow: 0 4px 10px rgba(0,0,0,0.04);"><br />
<br />
[[文件:HER2_HER3_Heterodimer.png|100px|HER2-HER3 异源二聚体]]<br />
</div><br />
<div style="font-size: 0.8em; color: #64748b; margin-top: 12px; font-weight: 600;">假激酶受体 / PI3K 激活子</div><br />
</div><br />
<br />
<table style="width: 100%; border-spacing: 0; border-collapse: collapse; font-size: 0.85em;"><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; border-bottom: 1px solid #f1f5f9; color: #475569; background-color: #f8fafc; width: 40%;">基因符号</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #f1f5f9; color: #0f172a;"><strong>ERBB3</strong></td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; border-bottom: 1px solid #f1f5f9; color: #475569; background-color: #f8fafc;">常用别名</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #f1f5f9; color: #0f172a;">HER3, LCCS2</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; border-bottom: 1px solid #f1f5f9; color: #475569; background-color: #f8fafc;">编码蛋白</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #f1f5f9; color: #0f172a;">Receptor tyrosine-protein kinase erbB-3</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; border-bottom: 1px solid #f1f5f9; color: #475569; background-color: #f8fafc;">染色体位置</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #f1f5f9; color: #0f172a;">12q13.2</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; border-bottom: 1px solid #f1f5f9; color: #475569; background-color: #f8fafc;">Entrez ID</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #f1f5f9; color: #1e40af;">2065</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; border-bottom: 1px solid #f1f5f9; color: #475569; background-color: #f8fafc;">HGNC ID</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #f1f5f9; color: #1e40af;">3431</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; border-bottom: 1px solid #f1f5f9; color: #475569; background-color: #f8fafc;">UniProt</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #f1f5f9; color: #1e40af;">P21860</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; border-bottom: 1px solid #f1f5f9; color: #475569; background-color: #f8fafc;">分子量</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #f1f5f9; color: #0f172a;">~148 kDa</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; color: #475569; background-color: #f8fafc;">关键配体</th><br />
<td style="padding: 8px 12px; color: #0f172a;">Neuregulin (NRG1)</td><br />
</tr><br />
</table><br />
</div><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">分子机制：沉默的合伙人</h2><br />
<br />
<p style="margin: 15px 0; text-align: justify;"><br />
ERBB3 在 ERBB 家族中扮演着独特的“支架”角色，其信号转导机制依赖于复杂的二聚化过程：<br />
</p><br />
<br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>配体诱导的构象改变：</strong> ERBB3 的胞外域结合配体 <strong>Neuregulin (NRG1)</strong>（亦称 Heregulin）。结合后，受体从“闭合”构象转变为“开放”构象，暴露出二聚化臂。</li><br />
<li style="margin-bottom: 12px;"><strong>专性异源二聚化：</strong> 由于 ERBB3 激酶活性极弱（缺乏催化所需的关键谷氨酸残基），它无法通过同源二聚化激活。它必须与激酶活性强的 <strong>HER2</strong>（无配体受体）或 EGFR 形成异源二聚体。<strong>HER2-HER3</strong> 被认为是该家族中致癌能力最强的二聚体组合。</li><br />
<li style="margin-bottom: 12px;"><strong>PI3K 通路的超级枢纽：</strong> 一旦被 HER2 磷酸化，HER3 的长 C 端尾部暴露出 6 个特定的酪氨酸磷酸化位点（YXXM 基序），这些位点能直接募集 <strong>PI3K</strong> 的 p85 调节亚基。这使得 HER3 成为该家族中激活 PI3K/AKT 生存通路效率最高的成员。</li><br />
</ul><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">临床景观：耐药与共驱动</h2><br />
<p style="margin: 15px 0; text-align: justify;"><br />
ERBB3 极少发生单独的驱动突变，它更多是作为其他 RTK（如 EGFR、HER2）的“逃生通道”或协同驱动因子出现。<br />
</p><br />
<div style="overflow-x: auto; margin: 30px auto; max-width: 90%;"><br />
<table style="width: 100%; border-collapse: collapse; border: 1.2px solid #cbd5e1; font-size: 0.95em; text-align: left;"><br />
<tr style="background-color: #f8fafc; border-bottom: 2px solid #0f172a;"><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #0f172a; width: 25%;">癌种</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #475569;">相关机制</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #1e40af;">临床意义</th><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">非小细胞肺癌 (NSCLC)</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">EGFR TKI 耐药</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">在奥希替尼（Osimertinib）耐药的肿瘤中，常观察到 HER3 的上调或其配体 NRG1 的过表达，通过激活 PI3K/AKT 绕过 EGFR 阻断。</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">HER2+ 乳腺癌</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">协同驱动</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">HER2 需要 HER3 来最大化其致癌潜能。HER3 的高表达与预后不良相关，帕妥珠单抗（Pertuzumab）的部分作用机制即是阻断 HER2-HER3 的二聚化。</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">结直肠癌 / 胃癌</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">过表达 / 突变</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">ERBB3 V104 突变在少数病例中被发现。HER3 过表达也是抗 EGFR 单抗（如西妥昔单抗）耐药的机制之一。</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">NRG1 融合肿瘤</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">配体融合</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">在胰腺癌和肺癌中，CD74-NRG1 等融合基因产生大量配体，自分泌激活 HER3，这类肿瘤对 HER3 靶向药高度敏感。</td><br />
</tr><br />
</table><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">治疗策略：抗体药物偶联物 (ADC) 的崛起</h2><br />
<p style="margin: 15px 0; text-align: justify;"><br />
由于 ERBB3 缺乏有效的激酶活性，传统的激酶抑制剂（TKI）难以直接靶向它。治疗策略主要集中在阻断其胞外域结合或利用其作为载体递送毒素。<br />
</p><br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>抗体药物偶联物 (ADC)：</strong> <br />
<br><strong>[[Patritumab deruxtecan]]</strong> (HER3-DXd, U3-1402)。<br />
<br><span style="font-size: 0.9em; color: #64748b;">*突破：利用 HER3 在癌细胞表面的广泛表达，将拓扑异构酶 I 抑制剂递送入胞。在 EGFR TKI 耐药的 NSCLC 患者（HERTHENA-Lung01 研究）中展现出显著疗效，是克服 EGFR 耐药的明星药物。</span><br />
</li><br />
<li style="margin-bottom: 12px;"><strong>双特异性抗体：</strong> <br />
<br><strong>[[Zenocutuzumab]]</strong> (MCLA-128)。同时靶向 HER2 和 HER3，采用“Dock & Block”机制阻断 NRG1 的结合。在 <strong>NRG1 融合</strong>阳性的肿瘤中显示出优异的抗肿瘤活性。</li><br />
<li style="margin-bottom: 12px;"><strong>二聚化抑制剂：</strong> 如帕妥珠单抗（Pertuzumab），通过结合 HER2 的二聚化结构域，间接阻止 HER2-HER3 复合物的形成。</li><br />
</ul><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">关键关联概念</h2><br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>假激酶 (Pseudokinase)：</strong> 指具有激酶同源结构但缺乏催化活性的蛋白，HER3 是经典代表。</li><br />
<li style="margin-bottom: 12px;"><strong>异源二聚体 (Heterodimer)：</strong> HER3 必须依赖的激活模式，HER2 是其最佳拍档。</li><br />
<li style="margin-bottom: 12px;"><strong>NRG1 (Neuregulin)：</strong> HER3 的特异性配体，驱动 HER3 活化的关键因子。</li><br />
<li style="margin-bottom: 12px;"><strong>PI3K/AKT：</strong> HER3 激活的主要下游效应通路，直接关联细胞生存。</li><br />
</ul><br />
<br />
<div style="font-size: 0.92em; line-height: 1.6; color: #1e293b; margin-top: 50px; border-top: 2px solid #0f172a; padding: 15px 25px; background-color: #f8fafc; border-radius: 0 0 10px 10px;"><br />
<span style="color: #0f172a; font-weight: bold; font-size: 1.05em; display: inline-block; margin-bottom: 15px;">学术参考文献与权威点评</span><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[1] <strong>Kraus MH, et al. (1989).</strong> <em>Isolation and characterization of ERBB3, a third member of the ERBB/epidermal growth factor receptor family.</em> <strong>PNAS</strong>. <br><br />
<span style="color: #475569;">[学术点评]：发现性文献。首次分离并鉴定了 ERBB3 基因，扩展了 EGFR 家族的版图。</span><br />
</p><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[2] <strong>Guy PM, et al. (1994).</strong> <em>Insect cell-expressed p180erbB3 is constitutively phosphorylated and binds phosphatidylinositol 3-kinase.</em> <strong>PNAS</strong>. <br><br />
<span style="color: #475569;">[学术点评]：机制里程碑。首次揭示了 ERBB3 与 PI3K 之间的直接且强力的相互作用，解释了其强效促生存信号的来源。</span><br />
</p><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[3] <strong>Holbro T, et al. (2003).</strong> <em>The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation.</em> <strong>PNAS</strong>. <br><br />
<span style="color: #475569;">[学术点评]：确立了“致癌单元”概念。证明 HER2 并非单打独斗，而是依赖 HER3 来驱动肿瘤增殖，为帕妥珠单抗的研发提供了理论基础。</span><br />
</p><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[4] <strong>Jänne PA, et al. (2022).</strong> <em>Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR-Mutated Non-Small Cell Lung Cancer.</em> <strong>Cancer Discovery</strong>. <br><br />
<span style="color: #475569;">[学术点评]：临床突破。HERTHENA-Lung01 相关数据，证明了靶向 HER3 的 ADC 药物在多线治疗失败的 EGFR 突变肺癌中具有显著疗效，开辟了耐药后治疗新路径。</span><br />
</p><br />
<br />
<p style="margin: 12px 0;"><br />
[5] <strong>Schocakat M, et al. (2021).</strong> <em>Neuregulin-1 (NRG1) Fusions as a Therapeutic Target in Solid Tumors.</em> <strong>Clinical Cancer Research</strong>. <br><br />
<span style="color: #475569;">[学术点评]：详细综述了 NRG1 融合在泛癌种中的分布及针对 HER3 轴的靶向治疗潜力。</span><br />
</p><br />
</div><br />
<br />
<div style="margin: 40px 0; border: 1.5px solid #0f172a; border-radius: 8px; overflow: hidden; font-size: 0.95em;"><br />
<div style="background-color: #0f172a; color: #ffffff; text-align: center; font-weight: bold; padding: 10px; letter-spacing: 1px;">ERBB3 · 知识图谱关联</div><br />
<div style="padding: 15px; background: #ffffff; line-height: 2.2; text-align: center; text-decoration: none;"><br />
[[ERBB2]] • [[PI3K/AKT]] • [[Patritumab deruxtecan]] • [[Neuregulin]] • [[假激酶]] • [[EGFR耐药]] • [[Zenocutuzumab]] • [[异源二聚体]]<br />
</div><br />
</div><br />
<br />
</div></div>
77921020